loading page

ACAT2 may be a novel predictive biomarker and treated target in lung adenocarcinoma
  • ZHONGCHAO WANG,
  • ZHUGEN CAO,
  • ZHAOXIA DAI
ZHONGCHAO WANG
Dalian Medical University
Author Profile
ZHUGEN CAO
Suqian First People's Hospital
Author Profile
ZHAOXIA DAI
The Second Hospital of Dalian Medical University

Corresponding Author:dzx21882003@163.com

Author Profile

Abstract

Background: Acyl-coenzyme A cholesterol acyltransferase (ACAT) is a membrane-binding enzyme, which localizes in the endoplasmic reticulum. ACAT2 can promote the progression of colon cancer, but its efficacy in lung adenocarcinoma(LUAD) is still not sure. Method: ACAT2 expression analysis was performed by TIMER2.0 database. GEPIA database was utilized to analyse co-relations between expression of ACAT2 and pathological stage of tumor. Kaplan-Meier analysis was analyzed its potential in clinical prognosis. CancerSEA database analysed correlations between expression of ACAT2 and functional status of different tumor displayed as a heatmap. The molecule interaction network analysis performed by the STRING tool. Results: ACAT2 was upregulated in patients with LUAD, and high expression of ACAT2 had a poor DFS and OS. Cox regression analysis indicated that the poor outcomes might be related to the tumour stage, nodal stage, distant metastatic stage. ACAT2 participated in biological process of cell cycle, DNA repair, DNA damage, proliferation. Enrichment pathway analysis showed four ACAT2-correlated genes, ACOX1, EHHADH, OXCT1, DLAT. Conclusion: ACAT2 might be a novel predictive biomarker and treated target.
20 Feb 2023Submitted to Cancer Reports
25 Feb 2023Review(s) Completed, Editorial Evaluation Pending
25 Feb 2023Assigned to Editor
25 Feb 2023Submission Checks Completed
03 Mar 2023Reviewer(s) Assigned